Financial Performance - The company's revenue for Q1 2022 was CNY 170,717,067.49, representing a 22.76% increase compared to CNY 139,064,824.26 in the same period last year[3] - Net profit attributable to shareholders decreased by 13.20% to CNY 26,734,954.17 from CNY 30,799,153.39 year-on-year[3] - The net profit for the first quarter of 2022 was CNY 26,747,582.62, a decrease of 13.6% compared to CNY 30,833,493.13 in the same period last year[20] - The operating profit for the first quarter was CNY 26,795,582.62, down from CNY 30,842,969.01, reflecting a decline of 13.3% year-over-year[20] - The company's basic earnings per share dropped by 67.14% to CNY 0.23 from CNY 0.70 in the same period last year[3] - The basic and diluted earnings per share for the first quarter were both CNY 0.23, down from CNY 0.70 in the previous year[21] Cash Flow - The net cash flow from operating activities surged by 482.66% to CNY 53,725,956.55, significantly higher than CNY 9,220,734.28 in the previous year[3] - The total cash flow from operating activities was CNY 53,725,956.55, significantly up from CNY 9,220,734.28 in the previous year, indicating a strong improvement in cash generation[24] - The company reported cash inflow from investment activities of CNY 423,881,553.42, compared to CNY 39,133,914.68 in the prior year, marking a substantial increase[24] - The net cash flow from financing activities was CNY 39,673,983.59, a turnaround from a net outflow of CNY 10,444,443.56 in the same quarter last year[25] - The total cash and cash equivalents at the end of the period reached CNY 605,921,777.86, a significant increase from CNY 171,300,923.23 at the end of the previous year[25] Assets and Liabilities - Total assets increased by 3.93% to CNY 1,950,254,096.69 from CNY 1,876,521,079.39 at the end of the previous year[3] - The total liabilities of the company amounted to RMB 481,808,825.00, up from RMB 438,923,390.32 at the beginning of the year, indicating an increase of 9.8%[17] - The company's fixed assets increased to RMB 826,366,345.60 from RMB 776,779,939.41, reflecting a growth of 6.4%[15] - The company's inventory increased to RMB 113,898,638.05 from RMB 107,921,860.27, showing a rise of 5.5%[15] Operating Costs and Expenses - Operating costs rose by 32.86% to CNY 143,765,250.74, primarily due to increased raw material costs and the production commencement of a new company[7] - Total operating costs for Q1 2022 were RMB 148,586,196.63, up 32.8% from RMB 111,933,934.05 in Q1 2021[19] - Research and development expenses for Q1 2022 were RMB 1,683,353.92, a decrease of 19.2% compared to RMB 2,081,209.43 in Q1 2021[19] - The company incurred interest expenses of CNY 1,142,550.36, which is a notable increase from CNY 142,444.44 in the same period last year[20] Shareholder Information - The company reported a total of 13,251 common shareholders at the end of the reporting period[10] - The company received government subsidies amounting to CNY 3,994,020.82, which are closely related to its normal business operations[5] - The company received CNY 4,100,000.00 from minority shareholders as part of capital contributions during the quarter[25] New Developments - The company established a new subsidiary in Guangxi with a registered capital of RMB 50 million to develop a modern agricultural edible fungus factory project[12] - The company reported a net profit increase, with retained earnings rising to RMB 477,345,631.89 from RMB 450,620,871.46, an increase of 5.9%[17]
华绿生物(300970) - 2022 Q1 - 季度财报